Divi's Laboratories Limited

NSE DIVISLAB.NS

Divi's Laboratories Limited EPS (Diluted) for the year ending March 31, 2024: USD 0.72

Divi's Laboratories Limited EPS (Diluted) is USD 0.72 for the year ending March 31, 2024, a -13.54% change year over year. EPS (Diluted) reflects the company's earnings per share adjusted for the potential dilution that could occur if all convertible securities were converted to common stock, providing a more conservative profitability measure.

Divi's Laboratories Limited EPS (Diluted) for the year ending March 31, 2023 was USD 0.84, a -43.10% change year over year.
Divi's Laboratories Limited EPS (Diluted) for the year ending March 31, 2022 was USD 1.47, a 43.87% change year over year.
Divi's Laboratories Limited EPS (Diluted) for the year ending March 31, 2021 was USD 1.02, a 48.37% change year over year.
Divi's Laboratories Limited EPS (Diluted) for the year ending March 31, 2020 was USD 0.69, a -6.17% change year over year.

Key data

Date	EPS (Diluted)	Shares (Diluted, Weighted)	Shares (Basic, Weighted)	Revenue

NSE: DIVISLAB.NS

Divi's Laboratories Limited

CEO	Dr. Kiran Satchandra Divi B. Pharm., M.Pharm
IPO Date	March 12, 2003
Location	India
Headquarters	Divi Towers
Employees	9,741
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Divi's Laboratories Limited manufactures and sells generic active pharmaceutical ingredients (APIs) and intermediates, and nutraceutical ingredients in India, the United States, Asia, Europe, and internationally. It also undertakes custom synthesis of APIs and intermediates; and supplies a range of carotenoids, as well as markets vitamins to nutritional, pharma, food/beverage, and feed industries. The company was formerly known as Divi's Research Center and changed its name to Divi's Laboratories Limited in 1994. The company was incorporated in 1990 and is headquartered in Hyderabad, India.

Key trends

Past 5 years